Original article Proliferation index revisited in neuroblastic tumors

Iżycka‐Świeszewska, Ewa; Lipska‐Ziętkiewicz, Beata S.; Adamkiewicz-Drożyńska, Elżbieta; Grajkowska, Wiesława; Hermann, Blanka; Bień, Ewa; Limon, Janusz

doi:10.5114/fn.2014.45565

Cited by 2 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an in vitro study, the expression levels of Topo‐IIα were found to be closely related to tumor cell proliferation and aggression . The relationship of expression of Topo‐II and Ki‐67 has also been reported in malignant tumors …”

Section: Introductionmentioning

confidence: 89%

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

et al. 2020

View full text Add to dashboard Cite

Background: Amrubicin chemotherapy is a treatment option for patients with non-small cell lung cancer (NSCLC) after third-line treatment in Japan. Although topoisomerase-II (Topo-II), a target of amrubicin, has been reported to be a prognostic or predictive marker for chemosensitivity and clinical outcomes in various types of malignancies, its effects in the Japanese population remain unknown. Methods: Data regarding 44 patients with advanced NSCLC treated with amrubicin between April 2004 and May 2014 were retrospectively analyzed. We evaluated the expression levels of Topo-II by immunohistochemical staining of tumor specimens obtained via biopsy or surgical resection. Results: The majority of enrolled patients were men (68%) with a median age of 67 (range, 43-78) years. The most common histological type was adenocarcinoma (70%). High Topo-II expression was observed in 13 (30%) of the 44 patients. The median progression-free survival and overall survival (OS) durations were 1.8 and 8.8 months, respectively. While there was no significant association between Topo-II expression and progression-free survival, patients with low Topo-II expression had significantly longer OS than did those with high Topo-II expression. Good performance status and low expression of Topo-II were all significantly associated with a favorable OS. Conclusion: Low expression of Topo-II was identified as an independent prognostic factor for longer survival in patients with NSCLC receiving amrubicin, a Topo-II inhibitor. Key pointsSignificant findings of the study:• The median progression-free survival and overall survival (OS) durations were 1.8 and 8.8 months, respectively. • While there was no significant association between Topo-II expression and progression-free survival, patients with low Topo-II expression had significantly longer OS than did those with high Topo-II expression. • Good performance status and low expression of Topo-II were all significantly associated with a favorable OS.

show abstract

Section: Introductionmentioning

confidence: 89%

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The pathological aspects of GNTs remain unclear however, case reports have found Olig2 commonly expressed in these tumors and thus lean more toward oligodendrogliomas. Three subtypes of GNTs that demonstrate Olig2 upregulation are dysembryoplastic neuroepithelial tumors (DNTs; Komori and Arai, 2013 ; Matsumura et al, 2013 ), papillary glioneuronal tumors (PGNTs; Tanaka et al, 2005 ; Chen et al, 2006 ; Gelpi et al, 2007 ; Iżycka-Świeszewska et al, 2008 ; Matsumura et al, 2013 ), and rosette-forming glioneuronal tumors ( Wang et al, 2009 ; Luan et al, 2010 ; Xiong et al, 2012 ; Matsumura et al, 2014 ).…”

Section: Introductionmentioning

confidence: 99%

“…Similarly, Olig2 expressing cells were also found in PGNTs suggesting that these tumors may be oligodendroglial or oligodendroglial-like. Histologically, PGNTs exhibit two distinct architectures: (1) pseudopapillary structures surrounded by (2) compact regions consisting of neuronal elements under different maturation stages ( Tanaka et al, 2005 ; Gelpi et al, 2007 ; Iżycka-Świeszewska et al, 2008 ; Marumo et al, 2013 ).…”

Section: Introductionmentioning

confidence: 99%

Biological functions of the Olig gene family in brain cancer and therapeutic targeting

Szu,

Tsigelny,

Wojcinski

et al. 2023

Front. Neurosci.

View full text Add to dashboard Cite

The Olig genes encode members of the basic helix–loop–helix (bHLH) family of transcription factors. Olig1, Olig2, and Olig3 are expressed in both the developing and mature central nervous system (CNS) and regulate cellular specification and differentiation. Over the past decade extensive studies have established functional roles of Olig1 and Olig2 in development as well as in cancer. Olig2 overexpression drives glioma proliferation and resistance to radiation and chemotherapy. In this review, we summarize the biological functions of the Olig family in brain cancer and how targeting Olig family genes may have therapeutic benefit.

show abstract

Original article Proliferation index revisited in neuroblastic tumors

Abstract: A b s t r a c t Neuroblastic tumors (NB) are the most common extracranial pediatric neural crest-derived tumors, with a dismal outcome in a substantial

Cited by 2 publications

References 27 publications

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin

Biological functions of the Olig gene family in brain cancer and therapeutic targeting

Contact Info

Product

Resources

About